Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Recruiting now · Phase 2
Conditions studied: Non-small Cell Lung Cancer (NSCLC)
In brief
This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active drug; no one will be given placebo. The treatment duration will be different for every participant, but an average of 12 months is expected. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of cycle is 3 weeks). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective.
Key facts
- Study ID
- NCT07288177
- Run by
- Genmab
- People needed
- 240
- Starts
- 2026-01-30
- Expected to finish
- 2028-11-22
- Last updated by the study team
- 2026-08-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Providence Medical Foundation (St. Joseph Heritage Healthcare) — Santa Rosa, California, United States (enrolling)
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia, United States (enrolling)
- Moffitt Cancer Center and Research Institute — Tampa, Florida, United States (enrolling)
- Emory Winship Cancer Institute — Atlanta, Georgia, United States (enrolling)
- St. Vincent Frontier Cancer Center — Billings, Montana, United States (enrolling)
- Nebraska Hematology-Oncology — Lincoln, Nebraska, United States (enrolling)
- Astera Cancer Care — East Brunswick, New Jersey, United States (enrolling)
- ONE Onc: New York Oncology Hematology — Albany, New York, United States (enrolling)
- Montefiore Medical Park — The Bronx, New York, United States (enrolling)
- UNC Health - University of North Carolina — Chapel Hill, North Carolina, United States (enrolling)
- Providence Portland Medical Center — Portland, Oregon, United States (enrolling)
- Providence Oncology & Hematology Care Clinic - Westside — West Haven-Sylvan, Oregon, United States (enrolling)
- Tennessee Oncology - Nashville St. Thomas Midtown Clinic — Nashville, Tennessee, United States (enrolling)
- Virginia Cancer Specialists — Fairfax, Virginia, United States (enrolling)
- St Andrews Medical Centre — Adelaide, Australia (enrolling)
- Icon Cancer Centre Hobart — Hobart, Australia (enrolling)
- Icon Cancer Care - Townsville — Hyde Park, Australia (enrolling)
- St John of God Murdoch Hospital — Murdoch, Australia (enrolling)
- GenesisCare North Shore — Saint Leonards, Australia (enrolling)
- Chu Helora Hospital La Louvière Site Jolimont — La Louvière, Belgium (enrolling)
- AZ Delta (Campus Wilgenstraat) — Roeselare, Belgium (enrolling)
- Shanghai East Hospital — Shanghai, Pudong, China (enrolling)
- Beijing Chest Tumor Hospital — Beijing, China (enrolling)
- Tianjin Medical University Cancer Institute and Hospital — Tianjin, China (enrolling)
- Compassionate Cancer Care Center — Fountain Valley, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.